The future of the global blue eye disease vaccine market looks promising with opportunities in the piglets and adult pigs markets.
- Within the type category, live vaccines is expected to witness higher growth over the forecast period due to better and longer-lasting immunity from live-attenuated vaccines in pigs.
- Within the application category, adult pigs is expected to witness the higher growth over the forecast period due to blue eye disease has an natural infected adult pig population, and outbreaks occur more often in these adult pigs.
- In terms of regions, APAC is expected to witness the highest growth over the forecast period due to there are a lot of big pig farms in China and southeast Asia.
Emerging Trends in Blue Eye Disease Vaccine Market
During the period 2025-2027, the blue eye disease vaccine market will transition from a specialized swine health concern in Mexico toward a more formal structure for prevention. Subsequently, the market will gain significance as herd security, speed of diagnosis, and reliability of vaccinations begin to better address the growing economic concerns of producers due to reproductive losses. Based on Lucintel’s assessment, market growth will be modest and will be primarily driven by regional disease pressure, as compared to broader market adoption.- Preventive Vaccination: In 2025, the veterinary programs in Mexico again promoted vaccination and quarantine as the blue eye disease control measures. Even though commercial products are available only in endemic production regions, where protection of the herd can reduce mortality and the disruption of the reproductive cycle of pigs, this focus will ensure that preventive measures remain the priority for the next 3-5 years.
- Regional Supply-chain Localization: Mexico is improving domestic supply of veterinary biologics, while import control and cold chain requirements are encouraging local supply chain partnerships. In 2024, Mexico accounted for 2.1 million tones of pork, creating an important clientele for Vaccine supply. Regional sourcing will influence the market by improving supply and reducing the time for restocking.
- Diagnostic-based Immunization: Clinical and serological tests, coupled with molecular diagnostics, allow laboratories to identify blue eye disease compared to other reproductive or respiratory diseases. Many veterinary diagnostics laboratories can provide PCR results in under 48 hours. Improved diagnostics will encourage the use of vaccines and eliminate the use of unnecessary therapeutic interventions in the years to come.
- Cold-chain Modernization: Vaccine suppliers provide improved services for the transport, inventory control, and rural veterinary delivery along Mexico’s fractured farm network. Most biologics require storage between 2 and 8 degrees Celsius, meaning temperature control is a business requirement. Increased investment in distribution will minimize product loss and increase availability beyond the larger, integrated producers.
- Integrated Herd Health: Producers integrate multiple aspects of vaccination, such as controlled animal movement, sanitation, testing of new stock, and herd-level records. Mexico’s commercial pig population was greater than 19 million animals in 2024 which provides a large enough market for integrated programs. The value of vaccines is enhanced when they are integrated into the routine of herd management.
Recent Developments in the Blue Eye Disease Vaccine Market
The market for the blue eye disease vaccine is small and concentrated in Mexico. The market for blue eye disease is also supported by diagnostics, veterinary biologics and contract manufacturing. Market players should exercise caution until 2025-2027. According to Lucintel, producers are focused on herd retention and reducing the financial burden of outbreaks due to the prevention-based demand.- Mexican Vendor Supply: While blue eye disease is primarily associated with production of pigs in Mexico, Mexican manufacturers are the commercial leaders in this market. SENASICA's 2025 animal health Program covered one hundred percent of the federally monitored commercial swine farms (January 2025). This will keep local procurement important, and to a greater extent, regulatory control and supply will be more important than a global supply.
- Improved Surveillance Collaboration: Veterinary labs have begun to integrate PCR testing with farm level vaccinations. The 2025 surveillance planned by the Mexican government included over 20 priority animal health programs (February 2025). This creates a need for diagnostic and vaccination services. Improved surveillance should lead to a reduction in unwanted vaccinations and an increase in vaccinations for boosters.
- Advanced Adjuvant Systems: Focus is in improving long-lasting vaccines for production systems. An industry report stated that spending on R&D in global animal health exceeded $1 billion in 2025 (June 2025). In the next three to five years, improvements in duration and ease of use will be more valuable than alternative vaccines.
- Veterinary Digital Distribution: More producers are sourcing biologics through integrated veterinary distribution channels versus farm-level suppliers. Leading animal health companies reported double-digit growth in digital sales for specific regions for 2025 (March 2026). This shift could mean better cold chain visibility and access to veterinary biologics for more small- / medium-scale farms located outside of Mexico's primary production corridors.
- Regional Manufacturing Resilience: Disruptions in the supply of veterinary biologics have inspired many animal health companies to position primary and secondary manufactured product in different regions, and to work with alternative supply chain partners. The European Commission approved funding for 17 animal health preparedness projects for 2025 (October 2025). This funding will create greater regional capacity for more flexible manufacturing and greater vaccine resilience. While the focus remains on the supply of these vaccines for the control and eradication of blue eye disease, more manufacturing capacity in the region would increase supply and reduce overreliance on a single supplier.
Strategic Growth Opportunities in the Blue Eye Disease Vaccine Market
The blue eye disease vaccine market is gaining commercial importance due to the growth of the swine industry and replenishment of breeding herds in Mexico, where farmers are increasingly interested in controlling reproductive losses. Between 2024 and 2026, Lucintel expects the investment of biosecurity, regional surveillance, and vaccines to create new opportunities in livestock health supply chains.- Breeding-herd Vaccines: Vaccines designed for breeding sows and replacement gilts can provide control over reproductive disruption, which can reduce the economic losses of production gaps. Mexico's projected pork production was 1.6 million metric tons for 2025 (January 2025). Demand for these vaccines will likely increase as integrated farms evaluate the impact of vaccination on weaning and farrowing.
- Regional Expansion: Suppliers can expand into the smaller, commercial farms in Latin America, beyond the established clusters in Mexico. Mexico is expected to import over 1 million metric tons of pork in 2025 (January 2025). The value of standardized, cold-chain supported vaccines will increase, along with the need for distributor training, over the next 3 - 5 years.
- Thermostable Vaccines: Vaccines which are shelf stable eliminate the cost of wastage associated with the refrigeration of vaccines. 80% of livestock is produced in low and middle income countries (WHAL 2025). Because the veterinarian services and products are not equally distributed, vaccines which can withstand heat will be easy to implement and encourage broader adoption.
- Contract Manufacturing: Outsourcing antigen production, filling, or packaging can help shorten local launch cycles to companies in the animal health space. The Mexican pharmaceutical market was expected to reach over US$10 billion by 2025 (February 2025). Forming strategic manufacturing partnerships will help suppliers provide cost-effective regional supply and respond to the findings of disease surveillance.
- Digital Herd Services: Bundling of vaccines with electronic records, laboratory confirmations, and reminders for scheduled re-vaccination is possible. According to estimates for 2025 (January), the pig inventory in Mexico was over 19 million. Services linked to data will enhance adherence and provide farm managers with evidence while also producing a stream of income beyond the first dose.
Blue Eye Disease Vaccine Market Drivers and Challenges
Growth of the blue eye disease vaccine market depends on health demand for animals, innovation in vaccines, surveillance for diseases, economics for production, and increasing regulations. Blue eye disease causes a decrease in productivity of the herd and increase in mortality, and so farmers want vaccines to mitigate the loss of the herd. Lucintel believes that the regional expansion of livestock, adoption of technology, and investments in biosecurity are significant drivers for the market. However, limited awareness, affordability, and difficult regulations will likely slow market growth, especially in developing and developed countries.The factors responsible for driving this market include:
- Increasing Demand for Disease Prevention: Farmers are more interested in vaccinating animals for the prevention of blue-eye disease because it helps protect breeding performance. It was reported that in 2025, porcine disease control efforts were constantly ongoing in Mexico confirming the need for preventive vaccinations (June 2025). It is anticipated that over the next 3-5 years the need for biosecurity will increase, along with the negative impact of outbreaks on farms, and will create demand for preventive vaccinations on commercial farms.
- Advances in Vaccine Technology: It is anticipated that the administration of vaccines will be simplified in the future with the use of thermostable vaccines and other improved delivery systems and antigen technologies. In 2025, veterinary biologics research continued to focus on improvements in cold-chain vaccines and formulations, including the creation of more user-friendly field vaccines (September 2025). Vaccines of this nature will help increase the confidence of producers that it will help achieve better herd health with less operational challenges.
- Regulatory and Veterinary Support: The creation of vaccination programs and disease reporting systems by the government, as well as veterinary consultations, would help create credibility and uniform control of diseases in emerging markets. Regulatory agencies made changes to requirements of veterinary biologics in 2025 which included changes related to quality, safety and manufacturing (October 2025). In the next 3-5 years, vendor availability will increase and institutional purchasing will follow with more consistent surveillance.
- Livestock Production Expansion: Intensive pork production enhances the economic importance of the prevention of communal disease infections. 2025 saw pork production stay above 120 million metric tons (December 2025), creating the need for herd health solutions. In the next 3-5 years, the growing of large commercial farms along with movement of animals to and from production units will help create the need for recurrent vaccinations and improve vaccine distribution.
- Manufacturing Efficiency and Cost Advantages: Although producing animal pharmaceuticals is costly, advances in manufacturing processes and fermentation and automation technologies may allow for the localized production of vaccines at lower costs and with greater reliability to the end user. In 2025, speed and quality assurance of veterinary biologics manufacturing was improved via automated systems implemented in a number of biologics production facilities (August 2025). These manufacturing efficiencies will create opportunities for suppliers to provide their services for economically sensitive markets, increasing vaccine market penetration and reducing vaccine shortages.
The challenges facing this market include:
- Limited Awareness and Diagnosis of Disease: Blue eye disease can possibly be mixed up with other porcine neurological, respiratory, or reproductive conditions. This can delay diagnosis and improve unproper treatment. For 2025, veterinary diagnostics focused on differential testing and continued this focus for 2025 because the identification of the disease is critical for the selection of the proper controls (July 2025). It is expected that for the next three to five years, there will be an imbalance of lab access and producer awareness. This will slow the adoption of the vaccine by smaller and weaker veterinary supported farms.
- Affordability and Distribution Issues: The high cost of the vaccine combined with the high cost to transport the vaccine and the cost to keep the vaccine cold during the transport to rural areas will discourage uninterrupted use by small to medium sized producers. Veterinary biologic shipments for 2025 focused on cold-chain logistics. Many rural areas have unsolved and undependable cold storage (November 2025). These issues will affect the market negatively by encouraging demand for locally produced low cost and thermostable vaccine.
- Regulatory and Supply Chain Issues: Different regulations and complications in the supply chain with different production standards can lead to different approved vaccines, shortages of specialized inputs, and limited availability of approved vaccines. 2025 was a challenging year for veterinary vaccine suppliers as they faced batch-release and document-related issues. Traditional veterinary vaccine supply chains are lengthy and fragmented; therefore, the time to market for approved vaccines is extended (May 2025). Market disruptions caused by supply chain and regulatory issues will increase prices in the short term, but standard harmonization may improve market access in the long term.
List of Blue Eye Disease Vaccine Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies blue eye disease vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the blue eye disease vaccine market companies profiled in this report include:
- Cahic
- Boehringer Ingelheim
- Msd Animal Health
- Chopper Biology
- Ceva
- Ringpu Biology
- Qilu Animal
Blue Eye Disease Vaccine Market by Segment
The study includes a forecast for the global blue eye disease vaccine market by type, application, and region.Type [Value ($B) from 2019 to 2035]:
- Live Vaccines
- Killed Vaccines
Application [Value ($B) from 2019 to 2035]:
- Piglets
- Adult Pigs
Region [Value ($B) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Blue Eye Disease Vaccine Market
Activities associated with the blue eye disease vaccine market are concentrated in Mexico while the five communities being studied are not affected. Lucintel reports that policy initiative support for animal disease surveillance, biologics manufacturing, and emergency preparedness that are planned to occur in 2025-2027, are starting to create a market infrastructure. Based on Lucintel’s most recent analysis, regulatory implementation at the country level retains the greatest market influence.- United States: The fiscal-year 2026 budget (May 2025) proposed $1.2 billion funding for the USDA APHIS to continue their commitment to federal investment in preparation for animal health. Unfortunately, no APHIS announcements have identified the approval of a blue eye disease vaccine. However, the regulatory and surveillance systems that currently exist are prepared to authorize blue eye disease vaccines for use or facilitate domestic production should the need for a rubulavirus vaccine become necessary.
- China: 2025 central policy for Chinese agriculture again made provisions to protect major livestock and veterinary biologics, and China retained the world’s largest pork industry with 421.7 million pigs as of the end of 2024 (January 2025). These provisions create a significant production base for future domestic vaccine research, licensure, and large scale manufacturing.
- Germany: The European Commission’s 2025 animal health work program continued to provide funding to support disease monitoring. Germany continued to implement the European Union Animal Health Law through its ongoing surveillance and biosecurity programs. Germany’s veterinary biologics and large scale swine production create a system that is prepared to evaluate the licensure of imported or manufactured vaccines.
- India: India’s Department of Animal Husbandry and Dairying devoted ₹3,400 crore to the National Animal Disease Control Programmed in the 2025-26 budget (February 2025) to help with vaccination and surveillance across all livestock segments. With the infrastructure of public procurement and cold-chain, future registration of porcine rubulavirus vaccines is possible as control of animal diseases expands.
- Japan: In its 2025 animal health program (April 2025), Japan’s Ministry of Agriculture, Forestry, and Fisheries mandated controls for swine diseases and veterinary surveillance. In 2024, Japan’s swine population was 8.9 million. These vet services have caused demand for validated diagnostics and preventive products to grow, although there have been no public 2025-2027 statements on a planned launch of a blue eye disease vaccine.
Features of the Global Blue Eye Disease Vaccine Market
- Market Size Estimates: blue eye disease vaccine market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: blue eye disease vaccine market size by type, application, and region in terms of value ($B).
- Regional Analysis: blue eye disease vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the blue eye disease vaccine market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the blue eye disease vaccine market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the blue eye disease vaccine market by type (live vaccines and killed vaccines), application (piglets and adult pigs), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Cahic
- Boehringer Ingelheim
- Msd Animal Health
- Chopper Biology
- Ceva
- Ringpu Biology
- Qilu Animal
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

LOADING...

